Sclerofibroma is an aggressive disease that usually grows in the deep soft tissues and is characterized by invasive growth and tends to recur locally after surgery, but does not metastasize. It tends to occur in the abdominal wall of adolescent and childbearing women. Lesions occurring in the abdominal wall usually occur in menstruating women. Most patients present with asymptomatic localized swelling. Most lesions progress slowly, and studies have shown no significant correlation between tumor recurrence and the boundaries of tumor resection. The initial finding of a sclerofibroma can be monitored if symptoms are not apparent. about 50% of sclerofibromas show no significant progression of disease within 5 years. Surgery is an option for patients who have surgically resectable sclerofibromas in critical areas. Patients who may be severely disabled by surgery may be considered for drug therapy or radiation therapy. Chemotherapy regimens based on methotrexate and vincristine and adriamycin may also be used. Although drugs such as cox2 inhibitors and triamcinolone acetonide can slow lesion progression, the overall response rate is poor. The efficacy of tyrosine kinase inhibitors such as Gleevec, Sotentan and Doxycycline in the treatment of sclerofibroblastoma is still being observed. Some studies have shown that although there is a relationship between the development of sclerofibroids and pregnancy, most sclerofibroids develop in a controlled manner and some of them gradually stop developing after delivery. Therefore, having a sclerofibroma is not a contraindication to pregnancy.